NO921969L - NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS - Google Patents

NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS

Info

Publication number
NO921969L
NO921969L NO92921969A NO921969A NO921969L NO 921969 L NO921969 L NO 921969L NO 92921969 A NO92921969 A NO 92921969A NO 921969 A NO921969 A NO 921969A NO 921969 L NO921969 L NO 921969L
Authority
NO
Norway
Prior art keywords
hiv
particles
recombinant
produced
retroviral
Prior art date
Application number
NO92921969A
Other languages
Norwegian (no)
Other versions
NO921969D0 (en
Inventor
Omar K Haffar
Shiu-Lok Hu
Allen W Senear
Bruce M Travis
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of NO921969D0 publication Critical patent/NO921969D0/en
Publication of NO921969L publication Critical patent/NO921969L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ikke-repllkerende rekombinantfremstilte retrovlrale partikler som har strukturelle, morfologiske og Immunologlske karakteristikker som er meget lignende de til naturlige humane retrovlrus, blir beskrevet. Fremgangsmåten omfatter koekspréssjon av modne retrovirale kjerne- og kappestrukturelle proteiner i mammalske vertsceller slik at de uttrykte retrovlrale proteinene forener seg til sammensatte knoppskytende retrovirale partikler. I en bestemt utførelse blir ikke-replikerende rekombinantfremstilte HIV-1 partikler fremstilt ved koinfeksjon av mammalske vertsceller med et rekombinant vacclnla virus som bærer* de human immunsviktvirus type l (HIV-1) gag og proteasegenene og en rekombinant vacclnla virus som bærer HIV-1 env genet. Disse Ikke-repllkerende rekombinantfremstilte partiklene har Immunologlske. og morfologiske karak- teristikker som er meget nær de til naturlige HIV-1, og er l stand til å blokkere infektivlteten av levende HIV in vitro og er meget sterkt immunogenlske in vlvo. De rekombinantfremstilte HIV-1 partiklene ifølge oppfinn- elsen kan bli anvendt som artlvirale midler og som immunogener i vakslneformuleringer som er effektive l hemming eller forhindring av infeksjon av HIV og/eller utviklingen av ervervet immunsvlktsyndrom (AIDS).Non-replicating recombinantly produced retroviral particles having structural, morphological and immunological characteristics very similar to those of natural human retroviruses are described. The method comprises coexpression of mature retroviral core and envelope structural proteins in mammalian host cells so that the expressed retroviral proteins join into composite bud-shoot retroviral particles. In a particular embodiment, non-replicating recombinant-produced HIV-1 particles are produced by co-infection of mammalian host cells with a recombinant vaccine virus carrying * the human immunodeficiency virus type 1 (HIV-1) gag and the protease genes and a recombinant vaccine virus carrying env gene. These Non-Replicating Recombinant-Prepared Particles have Immunological. and morphological characteristics that are very close to those of natural HIV-1 and are capable of blocking the infectiousness of live HIV in vitro and are highly immunogenic in vivo. The recombinant-produced HIV-1 particles of the invention can be used as artifact agents and as immunogens in vaccine formulations that are effective in inhibiting or preventing infection of HIV and / or the development of acquired immunodeficiency syndrome (AIDS).

NO92921969A 1989-11-20 1992-05-19 NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS NO921969L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43920589A 1989-11-20 1989-11-20
PCT/US1990/006798 WO1991007425A1 (en) 1989-11-20 1990-11-20 Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens

Publications (2)

Publication Number Publication Date
NO921969D0 NO921969D0 (en) 1992-05-19
NO921969L true NO921969L (en) 1992-06-26

Family

ID=23743729

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92921969A NO921969L (en) 1989-11-20 1992-05-19 NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS

Country Status (14)

Country Link
EP (1) EP0502105A4 (en)
JP (1) JPH05503629A (en)
KR (1) KR920703639A (en)
AU (1) AU636944B2 (en)
CA (1) CA2068713A1 (en)
ES (1) ES2052478T1 (en)
FI (1) FI922277A0 (en)
GR (1) GR930300005T1 (en)
HU (1) HUT60506A (en)
NO (1) NO921969L (en)
OA (1) OA09698A (en)
TW (1) TW216446B (en)
WO (1) WO1991007425A1 (en)
ZA (1) ZA909302B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431128B1 (en) * 1989-06-01 2003-03-26 Applied Biotechnology, Inc. Vector coding for self-assembled, defective, non-self-propagating viral particles
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
DE4124817A1 (en) * 1991-07-26 1993-01-28 Basf Ag AQUEOUS POLYMER DISPERSIONS
WO1993009238A1 (en) * 1991-11-08 1993-05-13 The Upjohn Company Feline leukemia virus vaccines
WO1993020840A1 (en) * 1992-04-14 1993-10-28 British Bio-Technology Limited Induction of ctl responses
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69435182D1 (en) * 1993-01-26 2009-02-26 Univ Pennsylvania Composition for administering genetic material
ES2249760T3 (en) 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) COMPOSITIONS AND PROCEDURES OF ADMINISTRATION OF GENETIC MATTERS.
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
US5858838A (en) 1998-02-23 1999-01-12 Taiwan Semiconductor Manufacturing Company, Ltd. Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
CN1185811A (en) * 1995-03-31 1998-06-24 H·沃尔夫 Antigen presentation system dependent on retrovirus-like particles
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ATE384795T1 (en) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic MODIFIED HIV ENV POLYPEPTIDES
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CN100446812C (en) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 MVA expressing modified HIV envelope, GAG and POL genes
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
ES2606511T3 (en) 2011-04-06 2017-03-24 Biovaxim Limited Pharmaceutical compositions to prevent and / or treat an HIV disease in humans
MA42502A (en) 2015-07-21 2018-05-30 Modernatx Inc VACCINES AGAINST INFECTIOUS DISEASE
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. ANTICANCER VACCINES
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
MA55321A (en) 2019-03-15 2022-01-19 Modernatx Inc RNA VACCINES AGAINST HIV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
JPH02203783A (en) * 1989-02-02 1990-08-13 Banyu Pharmaceut Co Ltd Cloned human t cell forming non-virulent aids virus having antigenicity
JP3140757B2 (en) * 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート Packaging defective HIV provirus, cell lines and uses thereof
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
CA2067778A1 (en) * 1989-10-16 1991-04-17 The Whitehead Institute For Biomedical Research Non-infectious hiv-1 particles and uses therefor

Also Published As

Publication number Publication date
GR930300005T1 (en) 1993-04-28
TW216446B (en) 1993-11-21
FI922277A7 (en) 1992-05-19
KR920703639A (en) 1992-12-18
WO1991007425A1 (en) 1991-05-30
AU6905591A (en) 1991-06-13
HUT60506A (en) 1992-09-28
ES2052478T1 (en) 1994-07-16
CA2068713A1 (en) 1991-05-21
HU9201659D0 (en) 1992-08-28
AU636944B2 (en) 1993-05-13
EP0502105A1 (en) 1992-09-09
FI922277A0 (en) 1992-05-19
NO921969D0 (en) 1992-05-19
ZA909302B (en) 1991-09-25
JPH05503629A (en) 1993-06-17
EP0502105A4 (en) 1993-02-24
OA09698A (en) 1993-08-30

Similar Documents

Publication Publication Date Title
DK33190A (en) HIV-3 RETROVIRUS AND ITS USE
Pinter et al. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1
Gallaher Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus
Haigwood et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies
Binley et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
JP3152433B2 (en) Vaccine and immunotherapy for preventing HIV infection
NO863803L (en) Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS).
WO1999027958A3 (en) Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
DK0495811T3 (en) Production of genetically engineered vaccines against AIDS and other retroviral diseases
CN101969996A (en) Polyvalent vaccine
ES2052478T1 (en) RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS.
FR2773156A1 (en) NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT
ES2140380T3 (en) DNA SEQUENCES THAT CODE MODIFIED RETROVIRIC POLYPEPTIDES AND VACCINES THAT CONTAIN THEM OR ADDED THEREOF.
DE60026199T2 (en) Synthetic genes for gagpol and their uses
CA2230925A1 (en) Fusion protein delivery system and uses thereof
De Rossi et al. Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism
JP2004509601A5 (en)
AU630861B2 (en) Recombinant hiv-2 polypeptides
SE9903031D0 (en) Peptide mixture and vaccine against a chronic viral infection
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
SE8701628D0 (en) MEANS OF ANALYSIS MM
WO1993005812A1 (en) Method to induce cytotoxic t lymphocytes specific for a broad array of hiv-1 isolates using hybrid synthetic peptides
Ball et al. EIAV genomic organization: further characterization by sequencing of purified glycoproteins and cDNA
Soutschek et al. Purification of a recombinantly produced transmembrane protein (gp41) of HIV I
Vogt et al. Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins